• Acquisition lays the foundation for building ResMed’s digital sleep medicine portfolio in Germany
• somnio’s digital health application focused on improving sleep in patients diagnosed with insomnia, closing gaps in care and providing an alternative to the prevailing drug therapy
• mementor is to be integrated into ResMed in Germany as an independent business area and serve as a platform for further developments in the field of digital health
  

MARTINSRIED, Germany and LEIPZIG, Germany, Aug. 02, 2022 (GLOBE NEWSWIRE) — ResMed RMDRMD)) today announced the takeover of the Leipzig company mementor; The transaction closed on Monday, August 1st. With this acquisition, ResMed strengthens its entire sleep portfolio in Germany with a digital solution for insomnia.

Founded in 2014 and based in Leipzig, Germany, mementor develops and owns the digital insomnia therapy solution somnio, Germany’s first and only permanently approved digital health application (DiGA) in the field of sleep medicine and is therefore reimbursable in Germany. It also complies with European Union data protection requirements under the General Data Protection Regulation (GDPR).

In Germany, around 1 in 10 people are affected by clinically relevant insomnia,¹ and nearly 3 in 10 people who suffer from sleep apnea.² Currently, only a small percentage of those affected receive the cognitive behavioral therapy for insomnia (CBT-I) recommended in the German S3 guideline. somnio fills a gap in care for insomnia sufferers and complements ResMed’s efforts to increase both awareness of the disease and access to effective home treatments.

The acquisition allows mementor to leverage ResMed Germany’s broader network to increase uptake of its approved digital therapy alternative for insomnia; somnio is now available in Germany via “app on prescription”. The clinical effectiveness of somnio has been proven in two randomized controlled trials, showing a sustained improvement in users’ sleep…